Memory Pharmaceuticals Provides Clinical Update on MEM 1003

Memory Pharmaceuticals is currently conducting a safety and tolerability study in Alzheimer's patients of MEM 1003, a neuronal L-type calcium channel modulator.

The results of this study will be used to assist in the design of a Phase IIa trial for MEM 1003. The safety and tolerability study is a single-center, randomized, double-blind, placebo-controlled clinical study. The study design consists of two segments, a double-blind, dose-escalation segment (the first segment) and double-blind, treatment segment (the second segment). Approximately 85 patients are expected to be tested over the course of the two segments of the study.

In addition to measuring safety and tolerability, a secondary objective of the study is to evaluate the acute neurocognitive function in Alzheimer's patients using a battery of standard cognitive tests. Pharmacokinetic measurements, or how the body absorbs, distributes, metabolizes and eliminates MEM 1003, and other observations from the safety and tolerability study, including the results of the cognitive tests, will be used to select the appropriate dose(s) and finalize design of the Phase IIa clinical study.